investorscraft@gmail.com

Arvinas, Inc. (ARVN)

Previous Close
$7.95
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)144.021712
Intrinsic value (DCF)7683068897429.0196642376068189
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

5 Science Park
New Haven, CT 06511
United States
Phone: 203 535 1456
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. John G. Houston Ph.D.
Full Time Employees: 430

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

HomeMenuAccount